There are 2789 resources available
1199P - Dose modification for the management of CNS adverse events in the phase III CROWN study of lorlatinib in non-small cell lung cancer (NSCLC)
Presenter: Ben Solomon
Session: ePoster Display
1201P - Real-world comparative effectiveness of 1L alectinib (ALC) vs crizotinib (CRZ) in patients (pts) with ALK+ advanced NSCLC with or without baseline CNS metastases (mets)
Presenter: Matthew Krebs
Session: ePoster Display
1202P - ALK-2016-CPHG: French cohort of advanced non-small cell lung cancer (aNSCLC) with ALK (ALK+) or ROS1 (ROS1+) gene rearrangement treated by crizotinib
Presenter: Didier Debieuvre
Session: ePoster Display
1203P - The analysis of ALK fusion variants in 4991 EGFR/MET mutation-negative non-squamous non-small cell lung carcinomas (NSCLCs)
Presenter: Evgeny Imyanitov
Session: ePoster Display
1204P - Cost-benefit analysis of ALK diagnosis in patients with non-small cell lung cancer in Spain
Presenter: Ana Laura Ortega Granados
Session: ePoster Display
1205P - Treatment sequencing and duration of subsequent tyrosine kinase inhibitors in ALK+ non-small cell lung cancer patients treated with brigatinib in the US
Presenter: Mohammad Jahanzeb
Session: ePoster Display
1084P - PLATForM: Descriptive analysis from a randomised, phase II study of novel spartalizumab combinations in previously treated unresectable/metastatic melanoma
Presenter: Caroline Robert
Session: ePoster Display
1085P - Ph I/II study of PI3K-β inhibitor GSK2636771 (G771) in combination with pembrolizumab (P) in patients (pts) with PTEN loss and melanoma or other advanced solid tumors
Presenter: Elizabeth Burton
Session: ePoster Display
1086P - IBI310 alone or in combination with sintilimab for advanced melanoma: Updated results of a phase Ia/Ib study
Presenter: BIN LIAN
Session: ePoster Display